GlassScriptPhysician profile
Rex M Roberson
NPI 1104875079
$6,520.83
in general payments reported to CMS, 2019-2025
20 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $296 · 2021: $1,206 · 2022: $957 · 2023: $1,136 · 2024: $901 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,250.14 | 2019-2025 | Precision 1, Total30, Precision7 |
| Coopervision INC. | $937.21 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $865.77 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $724.28 | 2022-2025 | Durysta, Vuity, Lumigan |
| Johnson & Johnson Vision Care, INC. | $453.52 | 2019-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $423.63 | 2019-2021 | |
| Notal Vision, INC. | $310.14 | 2021-2022 | |
| Glaukos Corporation | $303.30 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $246.75 | 2019-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $163.21 | 2025 | Xdemvy |
| Ivantis, INC | $158.63 | 2021 | |
| Astellas Pharma US INC | $125.25 | 2025 | Izervay |
| Horizon Therapeutics Plc | $123.88 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $119.95 | 2023-2024 | Acthar |
| Allergan, INC. | $112.36 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synergeyes, INC. | $94.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.36 | 2022 | |
| Oyster Point Pharma, INC. | $28.08 | 2023 | Tyrvaya |
| Shire North American Group INC | $24.80 | 2019 | |
| Ortho-Clinical Diagnostics, INC. | $17.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.